Ovid Therapeutics (NASDAQ:OVID) Trading Up 7.5% – Time to Buy?

Posted by George Bondi on Jul 9th, 2026

Ovid Therapeutics (NASDAQ:OVID – Get Free Report)’s share price rose 7.5% during mid-day trading on Tuesday . The company traded as high as $2.74 and last traded at $2.8060. Approximately 1,310,580 shares changed hands during trading, a decline of 51% from the average daily volume of 2,671,597 shares. The stock had previously closed at $2.61.

Analysts Set New Price Targets

A number of brokerages have commented on OVID. Roth Capital reiterated a “buy” rating and issued a $7.00 price target on shares of Ovid Therapeutics in a research note on Thursday, May 14th. Wall Street Zen raised Ovid Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. HC Wainwright increased their price target on Ovid Therapeutics from $2.00 to $4.00 and gave the company a “buy” rating in a research note on Thursday, April 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ovid Therapeutics in a research report on Tuesday, April 21st. Finally, Wedbush reissued an “outperform” rating and issued a $7.00 price target on shares of Ovid Therapeutics in a report on Wednesday, April 15th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $5.12.

View Our Latest Research Report on OVID

Ovid Therapeutics Stock Down 1.0%

The stock has a fifty day moving average price of $2.54 and a two-hundred day moving average price of $2.16. The company has a market cap of $504.67 million, a price-to-earnings ratio of -9.35 and a beta of 0.18. The company has a quick ratio of 10.17, a current ratio of 10.17 and a debt-to-equity ratio of 0.06.

Ovid Therapeutics (NASDAQ:OVID – Get Free Report) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.12) earnings per share for the quarter, hitting the consensus estimate of ($0.12). Ovid Therapeutics had a negative net margin of 240.11% and a negative return on equity of 22.51%. As a group, sell-side analysts expect that Ovid Therapeutics will post -0.5 EPS for the current year.

Institutional Trading of Ovid Therapeutics

Several large investors have recently modified their holdings of OVID. Bank of America Corp DE raised its stake in Ovid Therapeutics by 49.0% in the first quarter. Bank of America Corp DE now owns 290,432 shares of the company’s stock valued at $645,000 after purchasing an additional 95,532 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Ovid Therapeutics during the 1st quarter worth approximately $23,732,000. Ally Bridge Group NY LLC raised its position in Ovid Therapeutics by 57.9% during the first quarter. Ally Bridge Group NY LLC now owns 2,818,459 shares of the company’s stock valued at $6,257,000 after purchasing an additional 1,033,459 shares in the last quarter. ADAR1 Capital Management LLC lifted its stake in Ovid Therapeutics by 6.0% during the first quarter. ADAR1 Capital Management LLC now owns 4,544,113 shares of the company’s stock worth $10,088,000 after purchasing an additional 259,113 shares during the last quarter. Finally, Affinity Asset Advisors LLC boosted its holdings in shares of Ovid Therapeutics by 48.8% in the 1st quarter. Affinity Asset Advisors LLC now owns 10,636,318 shares of the company’s stock valued at $23,613,000 after purchasing an additional 3,486,318 shares in the last quarter. 72.24% of the stock is owned by institutional investors and hedge funds.

About Ovid Therapeutics

(Get Free Report)

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.